Outcomes and patterns of failure of sarcomatoid carcinoma of the larynx: The Mayo Clinic experience

Mauricio E. Gamez, Elizabeth Jeans, Michael L. Hinni, Eric Moore, Geoffrey Young, Daniel Ma, Lisa Mcgee, Matthew R. Buras, Samir H. Patel

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objectives/Hypothesis: Sarcomatoid carcinoma is a rare variant of squamous cell carcinoma of the head and neck. No consensus exists on its management. Our aim was to present our outcomes. Study Design: Retrospective study. Median follow-up 45 months. Methods: There were 38 patients with pathologically confirmed sarcomatoid carcinoma of the larynx treated at the Mayo Clinic from 1990 to 2014. Statistical analysis of overall survival (OS), progression-free survival (PFS), and local control (LC) were conducted using the Kaplan-Meier method. Results: The majority of patients were elderly males (92%) with a smoking history (74%) presenting with early-stage disease (71%). Surgery alone was the primary treatment in 27 patients (71%). Nine patients (25%) were treated with adjuvant radiation due to initial stage or high-risk pathologic features. Median radiation dose to the primary/surgical bed was 65 Gy (range, 60.3-75.0 Gy). A total of 15 patients (39%) had tumor recurrence, majority being local (n = 12). Sixty percent (n = 9) had multiple local recurrences. Five-year OS, PFS, and LC were 63%, 46%, and 72%, respectively. Subgroup analysis by stage I versus higher stages (II-IV) showed an OS of 80% versus 43% (P = .030), PFS of 65% versus 18% (P = .003), and LC of 84% versus 57% (P = .039). Conclusions: Sarcomatoid carcinoma of the larynx is rare, and frequently presents at an early stage in older men with history of smoking. Based on our outcomes and patterns of failure, it appears early-stage tumors are treated appropriately with single-modality therapy, whereas more advanced tumors require multimodality therapy. Validation in a larger cohort is warranted.

Original languageEnglish (US)
JournalLaryngoscope
DOIs
StateAccepted/In press - 2017

Fingerprint

Larynx
Carcinoma
Disease-Free Survival
Smoking
Radiation
Recurrence
Neoplasms
Survival
Survival Analysis
Consensus
Therapeutics
Retrospective Studies
History

Keywords

  • Larynx
  • Radiation therapy
  • Sarcoma
  • Surgery

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Gamez, M. E., Jeans, E., Hinni, M. L., Moore, E., Young, G., Ma, D., ... Patel, S. H. (Accepted/In press). Outcomes and patterns of failure of sarcomatoid carcinoma of the larynx: The Mayo Clinic experience. Laryngoscope. https://doi.org/10.1002/lary.26725

Outcomes and patterns of failure of sarcomatoid carcinoma of the larynx : The Mayo Clinic experience. / Gamez, Mauricio E.; Jeans, Elizabeth; Hinni, Michael L.; Moore, Eric; Young, Geoffrey; Ma, Daniel; Mcgee, Lisa; Buras, Matthew R.; Patel, Samir H.

In: Laryngoscope, 2017.

Research output: Contribution to journalArticle

Gamez, ME, Jeans, E, Hinni, ML, Moore, E, Young, G, Ma, D, Mcgee, L, Buras, MR & Patel, SH 2017, 'Outcomes and patterns of failure of sarcomatoid carcinoma of the larynx: The Mayo Clinic experience', Laryngoscope. https://doi.org/10.1002/lary.26725
Gamez, Mauricio E. ; Jeans, Elizabeth ; Hinni, Michael L. ; Moore, Eric ; Young, Geoffrey ; Ma, Daniel ; Mcgee, Lisa ; Buras, Matthew R. ; Patel, Samir H. / Outcomes and patterns of failure of sarcomatoid carcinoma of the larynx : The Mayo Clinic experience. In: Laryngoscope. 2017.
@article{0b7d6e1347424e8297ba54dbf00308c7,
title = "Outcomes and patterns of failure of sarcomatoid carcinoma of the larynx: The Mayo Clinic experience",
abstract = "Objectives/Hypothesis: Sarcomatoid carcinoma is a rare variant of squamous cell carcinoma of the head and neck. No consensus exists on its management. Our aim was to present our outcomes. Study Design: Retrospective study. Median follow-up 45 months. Methods: There were 38 patients with pathologically confirmed sarcomatoid carcinoma of the larynx treated at the Mayo Clinic from 1990 to 2014. Statistical analysis of overall survival (OS), progression-free survival (PFS), and local control (LC) were conducted using the Kaplan-Meier method. Results: The majority of patients were elderly males (92{\%}) with a smoking history (74{\%}) presenting with early-stage disease (71{\%}). Surgery alone was the primary treatment in 27 patients (71{\%}). Nine patients (25{\%}) were treated with adjuvant radiation due to initial stage or high-risk pathologic features. Median radiation dose to the primary/surgical bed was 65 Gy (range, 60.3-75.0 Gy). A total of 15 patients (39{\%}) had tumor recurrence, majority being local (n = 12). Sixty percent (n = 9) had multiple local recurrences. Five-year OS, PFS, and LC were 63{\%}, 46{\%}, and 72{\%}, respectively. Subgroup analysis by stage I versus higher stages (II-IV) showed an OS of 80{\%} versus 43{\%} (P = .030), PFS of 65{\%} versus 18{\%} (P = .003), and LC of 84{\%} versus 57{\%} (P = .039). Conclusions: Sarcomatoid carcinoma of the larynx is rare, and frequently presents at an early stage in older men with history of smoking. Based on our outcomes and patterns of failure, it appears early-stage tumors are treated appropriately with single-modality therapy, whereas more advanced tumors require multimodality therapy. Validation in a larger cohort is warranted.",
keywords = "Larynx, Radiation therapy, Sarcoma, Surgery",
author = "Gamez, {Mauricio E.} and Elizabeth Jeans and Hinni, {Michael L.} and Eric Moore and Geoffrey Young and Daniel Ma and Lisa Mcgee and Buras, {Matthew R.} and Patel, {Samir H.}",
year = "2017",
doi = "10.1002/lary.26725",
language = "English (US)",
journal = "Laryngoscope",
issn = "0023-852X",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Outcomes and patterns of failure of sarcomatoid carcinoma of the larynx

T2 - The Mayo Clinic experience

AU - Gamez, Mauricio E.

AU - Jeans, Elizabeth

AU - Hinni, Michael L.

AU - Moore, Eric

AU - Young, Geoffrey

AU - Ma, Daniel

AU - Mcgee, Lisa

AU - Buras, Matthew R.

AU - Patel, Samir H.

PY - 2017

Y1 - 2017

N2 - Objectives/Hypothesis: Sarcomatoid carcinoma is a rare variant of squamous cell carcinoma of the head and neck. No consensus exists on its management. Our aim was to present our outcomes. Study Design: Retrospective study. Median follow-up 45 months. Methods: There were 38 patients with pathologically confirmed sarcomatoid carcinoma of the larynx treated at the Mayo Clinic from 1990 to 2014. Statistical analysis of overall survival (OS), progression-free survival (PFS), and local control (LC) were conducted using the Kaplan-Meier method. Results: The majority of patients were elderly males (92%) with a smoking history (74%) presenting with early-stage disease (71%). Surgery alone was the primary treatment in 27 patients (71%). Nine patients (25%) were treated with adjuvant radiation due to initial stage or high-risk pathologic features. Median radiation dose to the primary/surgical bed was 65 Gy (range, 60.3-75.0 Gy). A total of 15 patients (39%) had tumor recurrence, majority being local (n = 12). Sixty percent (n = 9) had multiple local recurrences. Five-year OS, PFS, and LC were 63%, 46%, and 72%, respectively. Subgroup analysis by stage I versus higher stages (II-IV) showed an OS of 80% versus 43% (P = .030), PFS of 65% versus 18% (P = .003), and LC of 84% versus 57% (P = .039). Conclusions: Sarcomatoid carcinoma of the larynx is rare, and frequently presents at an early stage in older men with history of smoking. Based on our outcomes and patterns of failure, it appears early-stage tumors are treated appropriately with single-modality therapy, whereas more advanced tumors require multimodality therapy. Validation in a larger cohort is warranted.

AB - Objectives/Hypothesis: Sarcomatoid carcinoma is a rare variant of squamous cell carcinoma of the head and neck. No consensus exists on its management. Our aim was to present our outcomes. Study Design: Retrospective study. Median follow-up 45 months. Methods: There were 38 patients with pathologically confirmed sarcomatoid carcinoma of the larynx treated at the Mayo Clinic from 1990 to 2014. Statistical analysis of overall survival (OS), progression-free survival (PFS), and local control (LC) were conducted using the Kaplan-Meier method. Results: The majority of patients were elderly males (92%) with a smoking history (74%) presenting with early-stage disease (71%). Surgery alone was the primary treatment in 27 patients (71%). Nine patients (25%) were treated with adjuvant radiation due to initial stage or high-risk pathologic features. Median radiation dose to the primary/surgical bed was 65 Gy (range, 60.3-75.0 Gy). A total of 15 patients (39%) had tumor recurrence, majority being local (n = 12). Sixty percent (n = 9) had multiple local recurrences. Five-year OS, PFS, and LC were 63%, 46%, and 72%, respectively. Subgroup analysis by stage I versus higher stages (II-IV) showed an OS of 80% versus 43% (P = .030), PFS of 65% versus 18% (P = .003), and LC of 84% versus 57% (P = .039). Conclusions: Sarcomatoid carcinoma of the larynx is rare, and frequently presents at an early stage in older men with history of smoking. Based on our outcomes and patterns of failure, it appears early-stage tumors are treated appropriately with single-modality therapy, whereas more advanced tumors require multimodality therapy. Validation in a larger cohort is warranted.

KW - Larynx

KW - Radiation therapy

KW - Sarcoma

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=85021797504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021797504&partnerID=8YFLogxK

U2 - 10.1002/lary.26725

DO - 10.1002/lary.26725

M3 - Article

AN - SCOPUS:85021797504

JO - Laryngoscope

JF - Laryngoscope

SN - 0023-852X

ER -